Pyxis Oncology Valuation
| PYXS Stock | USD 1.89 0.01 0.53% |
Based on Macroaxis valuation methodology, the company appears to be undervalued. Pyxis Oncology holds a recent Real Value of $3.82 per share. The prevailing price of the company is $1.89. Our model determines the value of Pyxis Oncology from analyzing the company fundamentals such as Return On Equity of -0.39, current valuation of (11.29 M), and Shares Owned By Insiders of 24.54 % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Pyxis Oncology's valuation include:
Price Book 0.7352 | Enterprise Value -11.3 M | Enterprise Value Ebitda 1.0881 | Price Sales 6.9977 | Enterprise Value Revenue 5.0821 |
Undervalued
Today
Please note that Pyxis Oncology's price fluctuation is very risky at this time. Calculation of the real value of Pyxis Oncology is based on 3 months time horizon. Increasing Pyxis Oncology's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Pyxis stock is determined by what a typical buyer is willing to pay for full or partial control of Pyxis Oncology. Since Pyxis Oncology is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Pyxis Stock. However, Pyxis Oncology's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.89 | Real 3.82 | Target 9.67 | Hype 1.9 | Naive 0.57 |
The intrinsic value of Pyxis Oncology's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Pyxis Oncology's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Pyxis Oncology helps investors to forecast how Pyxis stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Pyxis Oncology more accurately as focusing exclusively on Pyxis Oncology's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Pyxis Oncology's intrinsic value based on its ongoing forecasts of Pyxis Oncology's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Pyxis Oncology's closest peers.
Pyxis Oncology Cash |
|
Pyxis Valuation Trend
Pyxis Oncology's real value is important for investors to make better decisions and a more accurate overall view of Pyxis Oncology's financial worth over time. Using both Pyxis Oncology's enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Pyxis Oncology Total Value Analysis
Pyxis Oncology is at this time anticipated to have valuation of (11.29 M) with market capitalization of 112.98 M, debt of 21.33 M, and cash on hands of 223.36 M. The negative valuation of Pyxis Oncology may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Pyxis Oncology fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(11.29 M) | 112.98 M | 21.33 M | 223.36 M |
Pyxis Oncology Asset Utilization
One of the ways to look at asset utilization of Pyxis is to check how much profit was generated for every dollar of assets it reports. Pyxis Oncology holds a negative application of assets of -0.21 pct., losing $0.002106 for each dollar of assets held by the company. Inadequate asset utilization implies the company is being less effective with each dollar of assets it holds. Put it differently, asset utilization of Pyxis Oncology shows how discouraging it operates for each dollar spent on its assets.Pyxis Oncology Ownership Allocation
Pyxis Oncology owns a total of 59.47 Million outstanding shares. Over half of Pyxis Oncology's outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Pyxis Oncology Profitability Analysis
Net Loss for the year was (73.79 M) with profit before overhead, payroll, taxes, and interest of 0.About Pyxis Oncology Valuation
The stock valuation mechanism determines Pyxis Oncology's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Pyxis Oncology based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Pyxis Oncology. We calculate exposure to Pyxis Oncology's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Pyxis Oncology's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -2 M | -2.1 M |
Pyxis Oncology Growth Indicators
Investing in growth stocks can be very risky. If the company such as Pyxis Oncology does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 39.9 M |
Pyxis Oncology Current Valuation Indicators
Pyxis Oncology's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Pyxis Oncology's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Pyxis Oncology, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Pyxis Oncology's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Pyxis Oncology's worth.Additional Tools for Pyxis Stock Analysis
When running Pyxis Oncology's price analysis, check to measure Pyxis Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pyxis Oncology is operating at the current time. Most of Pyxis Oncology's value examination focuses on studying past and present price action to predict the probability of Pyxis Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pyxis Oncology's price. Additionally, you may evaluate how the addition of Pyxis Oncology to your portfolios can decrease your overall portfolio volatility.